With Arcus Partnership vs. Buyout, Gilead Moves Beyond Remdesivir COVID-19 Focus24/7 Wall Street • 05/27/20
Gilead's remdesivir improves time to recovery for COVID-19 patients in peer-reviewed results, NIAID saysMarket Watch • 05/22/20
Galapagos and Gilead Sciences Post Successful Yet Disappointing Filgotinib ResultsThe Motley Fool • 05/21/20